Cancers, Vol. 13, Pages 5789: The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma
Cancers, Vol. 13, Pages 5789: The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma
Cancers doi: 10.3390/cancers13225789
Authors:
Ricki T. Krog
Noel F. C. C. de Miranda
Alexander L. Vahrmeijer
Nigel G. Kooreman
Advances in the treatment of pancreatic ductal adenocarcinoma (PDAC) using neoadjuvant chemoradiotherapy, chemotherapy, and immunotherapy have had minimal impact on the overall survival of patients. A general lack of immunogenic features and a complex tumor microenvironment (TME) are likely culprits for therapy refractoriness in PDAC. Induced pluripotent stem cells (iPSCs) should be explored as a means to advance the treatment options for PDAC, by providing representative in vitro models of pancreatic cancer development. In addition, iPSCs could be used for tailor-made cellular immunotherapies or as a source of tumor-associated antigens in the context of vaccination.
Source: Cancers - Category: Cancer & Oncology Authors: Ricki T. Krog Noel F. C. C. de Miranda Alexander L. Vahrmeijer Nigel G. Kooreman Tags: Review Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Immunotherapy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Stem Cell Therapy | Stem Cells | Vaccines